중동 및 아프리카 줄기세포 치료 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 줄기세포 치료 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • MEA
  • 350 Pages
  • 테이블 수: 41
  • 그림 수: 42

>중동 및 아프리카 줄기세포 치료 시장, 제품 유형별(골수 유래 중간엽 세포, 태반 또는 탯줄 줄기세포, 지방 조직 유래 중간엽 줄기세포 및 기타), 유형(이종 줄기세포 치료 및 자가 줄기세포 치료), 응용 분야(근골격계 질환, 급성 이식편대숙주병(AGVHD), 상처 및 부상, 심혈관 질환, 수술, 위장관 질환 및 기타), 최종 사용자(병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타), 유통 채널(직접 입찰, 제3자 유통업체) 산업 동향 및 2029년까지의 예측

중동 및 아프리카 줄기세포 치료 시장

시장 분석 및 통찰력

암, 근골격계 질환, 신경계 질환, 만성 손상, 심혈관 및 위장관 질환을 포함한 만성 질환은 입원, 장기 장애, 삶의 질 저하 및 사망으로 이어질 수 있습니다.

중동 및 아프리카 줄기세포 치료 시장

중동 및 아프리카 줄기세포 치료 시장

중간엽 줄기 세포는 여러 장기에 침투하여 통합되고, 심혈관, 폐, 척수 손상을 치료하고, 자가면역 질환, 간, 뼈 및 연골 질환의 상태를 개선합니다. 줄기 세포는 염증, 면역 체계 부전 및 조직 변성으로 인한 감염을 치료하는 강력한 도구입니다.

중동 및 아프리카 줄기세포 치료 시장 성장을 주도하는 요인은 만성 질환의 증가, 세포 치료 생산 시설에 대한 GMP 인증 승인 증가, 생명공학 부문의 성장, 줄기세포 기반 치료에 대한 임상 시험 증가 입니다. 그러나 시장 성장을 억제할 것으로 예상되는 요인은 줄기세포 기반 연구 비용의 증가, 줄기세포 치료를 받는 동안 직면하는 위험, 대안의 가용성입니다.

중동 및 아프리카 줄기세포 치료는 지원적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 중동 및 아프리카 줄기세포 치료 시장이 2022년에서 2029년까지의 예측 기간 동안 156만 달러의 가치에 도달하고 4.1%의 CAGR로 성장할 것으로 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 해

2020 (2019-2014까지 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

제품 유형별(골수 유래 중간엽 줄기 세포, 태반 또는 탯줄 줄기 세포, 지방 조직 유래 중간엽 줄기 세포 및 기타), 유형별(이종 줄기 세포 치료 및 자가 줄기 세포 치료), 적용 분야(근골격계 질환, 급성 이식편대숙주병(AGVHD), 상처 및 부상, 심혈관 질환, 수술, 위장 질환 및 기타), 최종 사용자(병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타), 유통 채널(직접 입찰, 제3자 유통업체)

적용 국가

 이스라엘

시장 참여자 포함

US Stem Cell, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc. 등

시장 정의

Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.

Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.

Middle East and Africa Stem Cell Therapy Market Dynamics

Drivers

  • Rise in prevalence and incidence of chronic diseases

Chronic diseases are common health conditions around the world. In the Middle East and Africa one in three adults suffers from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens. Chronic diseases—including cancer, musculoskeletal disorders, neurology disorders, chronic injuries, cardiovascular and gastrointestinal —can lead to hospitalization, long-term disability, reduced quality of life, and death.

The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung and spinal cord injuries, and improve the state of autoimmune diseases, liver, and bone and cartilage diseases. Stems cells are a potent tool for the treatment of diseases caused by inflammation, immune system failure, and or tissue degeneration

For instance,

  • In 2021, the World Health Organization (WHO) data, approximately 1.7 billion people were down with musculoskeletal disorders worldwide. Low back pain causes a high burden of musculoskeletal disorders
  • Rise in investment in research and development

The stem cell research is funded by the National Institute of Health (NIH) budget. The private sector also funds stem cell research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With stem cell therapies being a new field, an unbiased governmental body must supervise them. The FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries.

  • Growing biotechnology sector

People are getting more aware of their health, and also there is alertness for preventive healthcare. Emphasis on healthcare is gaining popularity. Awareness of disease and symptoms is essential for screening and early detection of infections due to advanced technology available in the healthcare system, such as stem cell technology which is helping the healthcare providers lead to higher survival rates. A large number of biotechnology companies focusing on the development of stem cell-based therapies are expected to drive the market's growth.

For instance,

  • In 2018, according to Centres for Medicare and Medicaid Services, NHE rose 4.6% to USD 3.60 trillion (USD 11,172.00 per person), accounting for 17.7% of GDP. National health spending will reach USD 6.20 trillion by 2028, with an average annual rate of 5.4% for 2019-2028

Opportunities

  • The rise in healthcare expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.

For instance,

• In 2019, according to Knoema, the health expenditure per capita for Israel was USD 3,456. Health expenditure per capita in Israel increased from USD 1,514 in 2000 to USD 3,456 in 2019, growing at an average annual rate of 4.66%

  • Strategic initiative by market players

The demand for stem cell therapy has increased due to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

  • In March 2022, Pluristem Inc. announced the positive phase I clinical trials for PLX-R18. The U.S. Food and Drug Administration (FDA) granted orphan drug designation to treat graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiation syndrome (ARS). The phase I clinical trials completed would result in the market player being qualified to conduct Phase II and III clinical trials and post-marketing approval

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.

Restraints/Challenges

  • The rise in cost of stem-cell based therapy research

Stem cell therapy is a developing and novel treatment option for the treatment of several disorders. Sometimes, the cost of the therapy is a concern for several conditions. The stem-cell therapy treatment procedures. The stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. The cost of stem cell therapy-based research therapy is not covered by medical insurance. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend.

For instance,

  • In 2022, the data by the Bioinformant states that the cost of autologous stem cell therapy in the U.S. is around USD 150,000
  • Lack of skilled professionals

The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.

Stem cell therapy encompasses a modern technology to replace damaged cells with healthy new ones. Nowadays, Stem cell therapies provide substantial benefits to patients suffering from a wide range of diseases such as neuronal disease, diabetes, and injuries such as brain trauma and spinal cord injuries.

The hematologists dealing in stem cell therapies must have received proper stem cell therapy administration training. They must be familiar with the on-site well-organized system for specific emergency administration of treatments. The stem cell therapy coordinator ensures that all relevant personnel must be informed when a patient receives therapy. The coordinator can be the health professionals, including state registered nurses.

The Middle East and Africa stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa stem cell therapy market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

In 2017, the data by the Middle East and Africa Burden of Disease (GBD) stated that lower back pain caused the maximum number of cases, followed by other musculoskeletal disorders (21.5%),

The Middle East and Africa stem cell therapy market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables available in the report. Direct or indirect impact analyses of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market during the growth period.

Impact of COVID-19 on the Middle East and Africa Stem Cell Therapy Market

During the pandemic, stem cell therapy had a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for stem cell therapy in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during COVID-19.

Recent Development

  • In March 2022, Pluristem Inc. announced the positive phase I clinical trials for PLX-R18. The U.S. Food and Drug Administration (FDA) granted orphan drug designation to treat graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiation syndrome (ARS). The phase I clinical trials completed would result in the market player being qualified to conduct Phase II and III clinical trials and post marketing approval.

Middle East and Africa Stem Cell Therapy Market Scope

The Middle East and Africa  stem cell therapy market is segmented into five segments based on product type, type, application, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Bone Marrow Derived Mesenchymal Stem Cells
  •  Placental or Umbilical Stem Cell
  •  Adipose Tissue Derived Mesenchymal Stem Cells
  •  Others

On the basis of product type, the Middle East and Africa  stem cell therapy market is segmented into bone marrow derived mesenchymal stem cells, placental or umbilical stem cell, adipose tissue derived mesenchymal stem cells, and others.

Type

  • Allogeneic Stem Cell Therapy
  •  Autologous Stem Cell Therapy

On the basis of type, the Middle East and Africa  stem cell therapy market is segmented into allogenic stem cell therapy, and autologous stem cell therapy.

Application

  • Musculoskeletal Disorders
  • Wounds and Injuries
  • Acute Graft-Versus-Host Disease (AGVHD)
  • Surgeries
  • Gastrointestinal Diseases
  • Cardiovascular Diseases
  • Others

중동 및 아프리카 줄기세포 치료 시장은 응용 분야별로 근골격계 질환, 상처 및 부상, 급성 이식편대숙주병(AGVHD), 수술, 위장관 질환, 심혈관 질환 등으로 구분됩니다.

최종 사용자

  • 병원 및 수술 센터
  •  치료 회사
  •  서비스 회사
  •  기타

중동 및 아프리카 줄기세포 치료 시장은 최종 사용자를 기준으로 병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 제3자 유통업체

줄기세포 치료 시장_시장

중동 및 아프리카 줄기세포 치료 시장은 유통 채널을 기준으로 직접 입찰과 제3자 유통업체로 구분됩니다.

중동 및 아프리카 줄기세포 치료 시장 지역 분석/통찰력

중동 및 아프리카 줄기세포 치료 시장을 분석하고, 위에 언급된 대로 지역, 제품 유형, 유형, 응용 분야, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

중동 및 아프리카 줄기세포 치료 시장 보고서에서 다루는 국가 중 하나는 이스라엘입니다. 이스라엘은 만성 질환의 증가와 의료비 지출 증가로 인해 시장을 지배할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 중동 및 아프리카 줄기세포 치료 시장 점유율 분석

중동 및 아프리카 줄기세포 치료 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 중동 및 아프리카의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 줄기세포 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

중동 및 아프리카 줄기세포 치료 시장의 주요 기업으로는 US Stem Cell, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용을 알아보려면 분석가 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 중동 및 아프리카 대 지역, 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 산업 전문가에게 문의하세요.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET

7 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES

8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH

8.1.3 GROWING BIOTECHNOLOGY SECTOR

8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES

8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES

8.2 RESTRAINTS

8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH

8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY

8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH

8.2.4 AVAILABILITY OF ALTERNATIVES

8.3 OPPORTUNITIES

8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

8.3.2 RISE IN HEALTHCARE EXPENDITURE

8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

8.4 CHALLENGES

8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY

8.4.2 STRINGENT REGULATIONS

9 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE

9.1 OVERVIEW

9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS

9.3 PLACENTAL/UMBILICAL STEM CELL

9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS

9.5 OTHERS

10 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY TYPE

10.1 OVERVIEW

10.2 ALLOGENEIC STEM CELL THERAPY

10.2.1 MUSCULOSKELETAL DISORDERS

10.2.2 WOUNDS AND INJURIES

10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

10.2.4 SURGERIES

10.2.5 GASTROINTESTINAL DISEASES

10.2.6 OTHER APPLICATION

10.3 AUTOLOGOUS STEM CELL THERAPY

10.3.1 CARDIOVASCULAR DISEASES

10.3.2 GASTROINTESTINAL DISEASES

10.3.3 OTHER APPLICATION

11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 MUSCULOSKELETAL DISORDERS

11.3 WOUNDS AND INJURIES

11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

11.5 SURGERIES

11.6 GASTROINTESTINAL DISEASES

11.7 CARDIOVASCULAR DISEASES

11.8 OTHER APPLICATION

12 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL AND SURGICAL CENTERS

12.3 THERAPEUTIC COMPANIES

12.4 SERVICES COMPANIES

12.5 OTHERS

13 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 THIRD PARTY DISTRIBUTORS

14 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY REGION

14.1 MIDDLE EAST AND AFRICA

14.1.1 ISRAEL

15 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021)

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 JCR PHARMACEUTICALS CO., LTD ( (2021)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.3 ORTHOFIX MEDICAL INC. (2021)

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 MEDIPOST (2021)

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS

17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021)

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 CORESTEM, INC. (2021)

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 PHARMICELL CO., LTD. (2021)

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.8 ANTEROGEN.CO., LTD (2021)

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENTS

17.9 ATHERSYS, INC.(2021)

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENTS

17.1 BRAINSTORM CELL LIMITED (2021)

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENTS

17.11 BIORESTORATIVE THERAPIES, INC. (2021)

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENTS

17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021)

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENTS

17.13 INTERNATIONAL STEMCELL CORPORATION (2021)

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 MESOBLAST LTD (2021)

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENTS

17.15 PLURISTEM INC.(2021)

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 STEMPEUTICS RESEARCH PVT LTD

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 U.S. STEM CELL, INC. (2021)

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 ISRAEL STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 36 ISRAEL STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 ISRAEL ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 ISRAEL AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 39 ISRAEL STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 40 ISRAEL STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 ISRAEL STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET : SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: DBMR POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET FROM 2022 TO 2029

FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET FROM 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET

FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022

FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020

FIGURE 17 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021

FIGURE 18 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)

FIGURE 19 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029)

FIGURE 20 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 21 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, 2021

FIGURE 22 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 23 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 24 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, 2021

FIGURE 26 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 27 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 28 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, 2021

FIGURE 30 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 31 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029)

FIGURE 32 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 33 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 34 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 35 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 36 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: SNAPSHOT (2021)

FIGURE 38 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2021)

FIGURE 39 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029)

FIGURE 40 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029)

FIGURE 41 MIDDLE EAST AND AFRICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022-2029)

FIGURE 42 MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Middle East and Africa Stem Cell Therapy Market size will be worth USD 1.56 million by 2029.
The Middle East and Africa Stem Cell Therapy Market growth rate will be 4.1% by 2029.
The Rise in prevalence and incidence of chronic diseases is the growth driver of the Middle East and Africa Stem Cell Therapy Market.
The product type, type, application, end user, and distribution channel are the factors on which the Middle East and Africa Stem Cell Therapy Market research is based.
The U.S. Stem Cell, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc are the major companies in the Middle East and Africa Stem Cell Therapy Market.